New hope for duchenne: Long-Term drug trial aims to slow muscle decline

NCT ID NCT07573631

First seen May 09, 2026 · Last updated May 12, 2026 · Updated 1 time

Summary

This study looks at the long-term safety and effects of a weekly infusion called BMN 351 in people with Duchenne muscular dystrophy (DMD) who can benefit from exon 51 skipping. Participants must have completed a previous BMN 351 study and stay on a stable steroid dose. The goal is to see if the drug helps maintain physical function over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENE MUSCULAR DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Fondazione Serena ETS - Centro Clinico NeMO Milano

    Milan, Italy

  • Great Ormond Street Hospital NHS Foundation Trust

    London, WC1N 3JH, United Kingdom

  • Hospital Sant Joan de Deu

    Barcelona, 08950, Spain

  • Hospital Viamed Santa Angela De la Cruz

    Seville, 41013, Spain

  • Leids Universitair Medisch Centrum

    Leiden, 2333 ZA, Netherlands

  • UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    Rome, Italy

  • Yeditepe University Kosuyolu Hospital

    Istanbul, Turkey, Turkey (Türkiye)

Conditions

Explore the condition pages connected to this study.